SEC Form 4 · accession 0001230486-26-000002
Elicio Therapeutics, Inc. · ELTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Julian Adams
Director
Period of report
Aug 31, 2026
Accepted (ET)
Sep 2, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001601485
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.70 | Aug 31, 2026 | A | 21,750 | A | — | Aug 31, 2036 | Common Stock | 21,750 | 21,750 | D |
Explanation of responses
- F1The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.